Myriad Genetics’ Earnings Call: Mixed Signals and Future Prospects

Myriad Genetics ((MYGN)) has held its Q3 earnings call. Read on for the main highlights of the call.

The recent earnings call for Myriad Genetics painted a mixed picture of the company’s current standing and future prospects. While the company showcased strong operational efficiencies and promising strategic initiatives, these were tempered by current revenue declines and challenges in specific segments, particularly prenatal testing. Despite these hurdles, the company remains optimistic about its future growth potential.

Strong Volume Growth in Key Segments

Myriad Genetics reported notable volume growth in key segments, with MyRisk in oncology experiencing a 16% year-over-year increase and MyRisk for unaffected growing by 11%. Additionally, GeneSight volume rose by 8%, marking an acceleration from the first half of 2025. These figures highlight the company’s success in expanding its reach and effectiveness in these critical areas.

High Adjusted Gross Margin

The company achieved an impressive adjusted gross margin of 70.1% in the third quarter, underscoring its operational efficiency and a favorable test mix. This high margin reflects Myriad Genetics’ ability to manage costs effectively while maintaining a strong product offering.

Strategic Partnerships and Product Launches

Myriad Genetics is actively pursuing growth through strategic partnerships and product innovations. The company has entered into a collaboration with SOPHiA GENETICS and is preparing to launch an updated MyRisk test and a new Prolaris prostate cancer test in 2026. These initiatives are expected to drive future growth and enhance the company’s competitive position.

Positive Adjusted EBITDA and Free Cash Flow

The company reported an adjusted EBITDA of $10.3 million and adjusted free cash flow of $18.6 million, showcasing its profitability and ability to generate cash. These financial metrics highlight the company’s strong operational performance and its potential for sustained financial health.

Reaffirmation of 2025 Financial Guidance

Myriad Genetics reaffirmed its full-year revenue guidance for 2025, projecting annual revenue between $818 million and $828 million. The company also maintained its gross margin range of 69.5% to 70% and adjusted EBITDA guidance of $27 million to $33 million. This reaffirmation signals confidence in its strategic direction and financial outlook.

Revenue Decline

Despite the positive developments, Myriad Genetics faced a 4% year-over-year decline in total revenue for the third quarter, amounting to $205.7 million. This decline was primarily attributed to a challenging comparison with the previous year and the impact of UnitedHealthcare’s policy change on GeneSight coverage.

Average Revenue Per Test Decrease

The average revenue per test decreased by 7% year-over-year, influenced by shifts in payer mix and the policy change by UnitedHealthcare. This decrease presents a challenge that the company needs to address to maintain its revenue growth.

Challenges with Prenatal Testing

The volume growth for legacy prenatal products remained flat year-over-year, indicating ongoing challenges in this segment. Although there were some improvements from previous quarters, the company continues to face hurdles in achieving significant growth in prenatal testing.

Forward-Looking Guidance

Looking ahead, Myriad Genetics is focused on maintaining profitability and driving growth through its cancer care continuum strategy. The company reported a 3% increase in testing volumes, with significant growth in MyRisk oncology and GeneSight volumes. Operating expenses were reduced by $1 million year-over-year, demonstrating a disciplined approach to cost management. The company remains committed to its 2025 financial guidance and continues to invest in strategic initiatives to support future growth.

In conclusion, Myriad Genetics’ earnings call highlighted a balanced view of its current challenges and future opportunities. While revenue declines and challenges in prenatal testing pose hurdles, the company’s strong operational efficiencies, strategic partnerships, and reaffirmed financial guidance provide a foundation for optimism. Investors and stakeholders will be keenly watching how the company navigates these dynamics in the coming quarters.